Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444844/ https://www.ncbi.nlm.nih.gov/pubmed/37607920 http://dx.doi.org/10.1038/s41408-023-00898-4 |
_version_ | 1785094043281129472 |
---|---|
author | Khan, I. Kaempf, A. Raghuwanshi, S. Chesnokov, M. Zhang, X. Wang, Z. Domling, A. Tyner, J. W. Camacho, C. Gartel, A. L. |
author_facet | Khan, I. Kaempf, A. Raghuwanshi, S. Chesnokov, M. Zhang, X. Wang, Z. Domling, A. Tyner, J. W. Camacho, C. Gartel, A. L. |
author_sort | Khan, I. |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-10444844 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-104448442023-08-24 Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance Khan, I. Kaempf, A. Raghuwanshi, S. Chesnokov, M. Zhang, X. Wang, Z. Domling, A. Tyner, J. W. Camacho, C. Gartel, A. L. Blood Cancer J Correspondence Nature Publishing Group UK 2023-08-22 /pmc/articles/PMC10444844/ /pubmed/37607920 http://dx.doi.org/10.1038/s41408-023-00898-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Correspondence Khan, I. Kaempf, A. Raghuwanshi, S. Chesnokov, M. Zhang, X. Wang, Z. Domling, A. Tyner, J. W. Camacho, C. Gartel, A. L. Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance |
title | Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance |
title_full | Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance |
title_fullStr | Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance |
title_full_unstemmed | Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance |
title_short | Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance |
title_sort | favorable outcomes of npm1(mut) aml patients are due to transcriptional inactivation of foxm1, presenting a new target to overcome chemoresistance |
topic | Correspondence |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444844/ https://www.ncbi.nlm.nih.gov/pubmed/37607920 http://dx.doi.org/10.1038/s41408-023-00898-4 |
work_keys_str_mv | AT khani favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance AT kaempfa favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance AT raghuwanshis favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance AT chesnokovm favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance AT zhangx favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance AT wangz favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance AT domlinga favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance AT tynerjw favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance AT camachoc favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance AT gartelal favorableoutcomesofnpm1mutamlpatientsareduetotranscriptionalinactivationoffoxm1presentinganewtargettoovercomechemoresistance |